Malaria Clinical Trial
— TIRSOfficial title:
From Malaria Control to Sustainable Elimination: Cluster Randomised Trial Comparing Targeted Versus Generalised Vector Control in South Africa
| NCT number | NCT02556242 |
| Other study ID # | EPIDZC8610 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 4 |
| First received | |
| Last updated | |
| Start date | October 2015 |
| Est. completion date | July 2017 |
| Verified date | July 2020 |
| Source | London School of Hygiene and Tropical Medicine |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Since 2000, annual numbers of malaria cases in South Africa have sharply declined to about
5,000, with case numbers fairly stable since 2007. The principal malaria prevention strategy
has consisted of generalised Indoor Residual Spraying (IRS) of all houses in malaria endemic
districts. As recent case data indicate that the levels of transmission in many districts
have been reduced to very low levels, the continuation of untargeted IRS in areas where there
is little or no evidence of recent transmission may be unwarranted. Efforts to eliminate
malaria will only be sustainable if mass prevention efforts can be scaled down in an
evidence-based manner, whilst maintaining or enhancing high sensitivity of the surveillance
system of the disease. This trial will provide scientific evidence for targeted malaria
prevention responding to localised transmission in pre-elimination settings, compared to
continuation of generalised IRS of all houses.
Two methods of IRS delivery for community malaria prevention will be compared through an
open-label cluster-randomised trial consisting of two study arms with 30 clusters per arm of
approximately 8,000 inhabitants per cluster.
Comparison is on the basis of non-inferiority by showing that malaria incidence in the
targeted IRS arm is no higher than malaria incidence in the generalised IRS arm within a
specified margin of difference, and on the basis of superiority showing that the proportion
of houses targeted for spraying is higher in the intervention than the reference arm.
Neighbourhood investigation in response to each locally acquired case in the intervention
arm, and comparison neighbourhoods in the reference arm, will include testing for antibody
sero-conversion to malarial antigens to assess whether cases arise in communities with long
term exposure to malaria parasites.
The trial will be carried out in the South African provinces of Limpopo and Mpumalanga, in
localities which have average reported incidence of malaria of <5 cases per 1000 per annum
over the past five years.
| Status | Completed |
| Enrollment | 393387 |
| Est. completion date | July 2017 |
| Est. primary completion date | June 2017 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | N/A and older |
| Eligibility |
Inclusion criteria 1. Entire communities of approximately 8000 persons 2. Residents in malaria endemic districts of Limpopo and Mpumalanga Province 3. Areas with local malaria incidence <5 cases per 1000 per year on average over 5 years |
| Country | Name | City | State |
|---|---|---|---|
| South Africa | Provincial Malaria Control Programme | Nelspruit | Mpumalnga |
| South Africa | Provincial Malaria Control Programme | Tzaneen | Limpopo |
| Lead Sponsor | Collaborator |
|---|---|
| London School of Hygiene and Tropical Medicine | Medical Research Council, National Department of Health, South Africa, National Institute for Communicable Diseases, South Africa, University of Witwatersrand, South Africa |
South Africa,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Malaria incidence, by routine passive case detection, of clinical malaria (fever =37.5°C, or history of fever (48 hours), in the presence of parasitaemia confirmed by RDT or microscopy). | Communities will be followed for up to 20 months | ||
| Secondary | Intervention costs per 1,000 households and cost-effectiveness of reactive, targeted indoor residual spraying (TIRS) compared to generalised IRS (GIRS) | Cost of spray operations will be determined in each study arm | Up to 20 months | |
| Secondary | Proportion of structures targeted for IRS unsprayed | Up to 20 months whenever reactive spraying is triggered | ||
| Secondary | Household compliance (not painting, washing, re-plastering ) | In a representative sample household survey in all clusters, a questionnaire will be used in which householders will be asked whether they painted, re-plastered or washed walls after spraying | By cross sectional household survey after 18 months | |
| Secondary | Householder acceptability of IRS | In a representative sample household survey in all clusters, a questionnaire will be used in which householders will be asked whether they want their house sprayed with insecticide in future | By cross sectional household survey after 18 months | |
| Secondary | If unsprayed, proportions due to refusals, spray teams not making contact and spray teams not calling back | In a representative sample household survey in all clusters, a questionnaire will be used in which householders whose houses remained unsprayed will be asked whether this was because they refused or because spray teams did not make contact or did not call back if they were away | By cross sectional household survey after 18 months | |
| Secondary | Sero-prevalence of antibodies to malaria antigens AMA-1 and MSP-1-19 | In a representative sample household survey in all clusters, a filter paper dried blood spot a will be taken from a sample of individuals of all ages, subject to informed written consent | By cross sectional household survey after 18 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
| Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
| Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
| Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
| Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
| Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
| Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
| Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
| Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
| Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
| Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
| Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
| Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
| Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
| Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
| Completed |
NCT02605720 -
Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns
|
Phase 3 |